DK2515957T3 - Ændring af enzymatiske tværbindere for styring af egenskaber ved tværbundne matrixer - Google Patents
Ændring af enzymatiske tværbindere for styring af egenskaber ved tværbundne matrixer Download PDFInfo
- Publication number
- DK2515957T3 DK2515957T3 DK10814706.7T DK10814706T DK2515957T3 DK 2515957 T3 DK2515957 T3 DK 2515957T3 DK 10814706 T DK10814706 T DK 10814706T DK 2515957 T3 DK2515957 T3 DK 2515957T3
- Authority
- DK
- Denmark
- Prior art keywords
- enzyme
- matrix
- modified
- polymer
- mpeg
- Prior art date
Links
- 239000011159 matrix material Substances 0.000 title claims description 113
- 230000002255 enzymatic effect Effects 0.000 title description 13
- 230000008859 change Effects 0.000 title description 4
- 102000004190 Enzymes Human genes 0.000 claims description 332
- 108090000790 Enzymes Proteins 0.000 claims description 332
- 238000004132 cross linking Methods 0.000 claims description 130
- 229920001223 polyethylene glycol Polymers 0.000 claims description 127
- 108010010803 Gelatin Proteins 0.000 claims description 122
- 229920000159 gelatin Polymers 0.000 claims description 122
- 235000019322 gelatine Nutrition 0.000 claims description 122
- 235000011852 gelatine desserts Nutrition 0.000 claims description 122
- 239000002202 Polyethylene glycol Substances 0.000 claims description 119
- 239000008273 gelatin Substances 0.000 claims description 117
- 229920000642 polymer Polymers 0.000 claims description 101
- 230000006320 pegylation Effects 0.000 claims description 81
- 102000004169 proteins and genes Human genes 0.000 claims description 66
- 108090000623 proteins and genes Proteins 0.000 claims description 66
- 235000018102 proteins Nutrition 0.000 claims description 61
- 239000000758 substrate Substances 0.000 claims description 49
- 230000001965 increasing effect Effects 0.000 claims description 45
- 239000000203 mixture Substances 0.000 claims description 43
- 230000004048 modification Effects 0.000 claims description 42
- 238000012986 modification Methods 0.000 claims description 42
- 108060008539 Transglutaminase Proteins 0.000 claims description 40
- 102000003601 transglutaminase Human genes 0.000 claims description 40
- 238000000034 method Methods 0.000 claims description 38
- 210000001519 tissue Anatomy 0.000 claims description 35
- 230000015572 biosynthetic process Effects 0.000 claims description 34
- 241001465754 Metazoa Species 0.000 claims description 25
- 229920001427 mPEG Polymers 0.000 claims description 22
- 239000000463 material Substances 0.000 claims description 21
- 238000009739 binding Methods 0.000 claims description 20
- 235000018977 lysine Nutrition 0.000 claims description 17
- 229920002307 Dextran Polymers 0.000 claims description 15
- 230000000813 microbial effect Effects 0.000 claims description 15
- 150000004676 glycans Chemical class 0.000 claims description 13
- 229920001282 polysaccharide Polymers 0.000 claims description 13
- 239000005017 polysaccharide Substances 0.000 claims description 13
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 11
- 125000003588 lysine group Chemical class [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims description 11
- 241000251468 Actinopterygii Species 0.000 claims description 10
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 10
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 10
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 10
- 229920001577 copolymer Polymers 0.000 claims description 9
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 9
- 108010035532 Collagen Proteins 0.000 claims description 8
- 102000008186 Collagen Human genes 0.000 claims description 8
- 210000000988 bone and bone Anatomy 0.000 claims description 8
- 229920001436 collagen Polymers 0.000 claims description 8
- 125000000524 functional group Chemical group 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 8
- 230000001590 oxidative effect Effects 0.000 claims description 7
- 102000013415 peroxidase activity proteins Human genes 0.000 claims description 7
- 108040007629 peroxidase activity proteins Proteins 0.000 claims description 7
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 claims description 6
- 229920001287 Chondroitin sulfate Polymers 0.000 claims description 6
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 6
- 229940059329 chondroitin sulfate Drugs 0.000 claims description 6
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 6
- 239000012948 isocyanate Substances 0.000 claims description 6
- 230000036961 partial effect Effects 0.000 claims description 6
- -1 succinimidyl esters Chemical class 0.000 claims description 6
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 5
- 229920002971 Heparan sulfate Polymers 0.000 claims description 5
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 5
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 5
- 229920000288 Keratan sulfate Polymers 0.000 claims description 5
- 108010029541 Laccase Proteins 0.000 claims description 5
- 102000003425 Tyrosinase Human genes 0.000 claims description 5
- 108060008724 Tyrosinase Proteins 0.000 claims description 5
- 229920006037 cross link polymer Polymers 0.000 claims description 5
- 229920000669 heparin Polymers 0.000 claims description 5
- 229960002897 heparin Drugs 0.000 claims description 5
- 229920002674 hyaluronan Polymers 0.000 claims description 5
- 229960003160 hyaluronic acid Drugs 0.000 claims description 5
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 5
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 5
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 5
- KXCLCNHUUKTANI-RBIYJLQWSA-N keratan Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@H](COS(O)(=O)=O)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@H](O[C@@H](O[C@H]3[C@H]([C@@H](COS(O)(=O)=O)O[C@@H](O)[C@@H]3O)O)[C@H](NC(C)=O)[C@H]2O)COS(O)(=O)=O)O[C@H](COS(O)(=O)=O)[C@@H]1O KXCLCNHUUKTANI-RBIYJLQWSA-N 0.000 claims description 5
- 230000000873 masking effect Effects 0.000 claims description 5
- 238000007789 sealing Methods 0.000 claims description 5
- 108010088751 Albumins Proteins 0.000 claims description 4
- 102000009027 Albumins Human genes 0.000 claims description 4
- 229920000045 Dermatan sulfate Polymers 0.000 claims description 4
- AVJBPWGFOQAPRH-FWMKGIEWSA-N alpha-L-IdopA-(1->3)-beta-D-GalpNAc4S Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@H](OS(O)(=O)=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](C(O)=O)O1 AVJBPWGFOQAPRH-FWMKGIEWSA-N 0.000 claims description 4
- 229940051593 dermatan sulfate Drugs 0.000 claims description 4
- 239000001923 methylcellulose Substances 0.000 claims description 4
- 235000010981 methylcellulose Nutrition 0.000 claims description 4
- 230000035322 succinylation Effects 0.000 claims description 4
- 238000010613 succinylation reaction Methods 0.000 claims description 4
- 229920001059 synthetic polymer Polymers 0.000 claims description 4
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 claims description 3
- TZXJJSAQSRHKCZ-UHFFFAOYSA-N 2-methoxyethyl 4-methylbenzenesulfonate Chemical compound COCCOS(=O)(=O)C1=CC=C(C)C=C1 TZXJJSAQSRHKCZ-UHFFFAOYSA-N 0.000 claims description 3
- RFRMMZAKBNXNHE-UHFFFAOYSA-N 6-[4,6-dihydroxy-5-(2-hydroxyethoxy)-2-(hydroxymethyl)oxan-3-yl]oxy-2-(hydroxymethyl)-5-(2-hydroxypropoxy)oxane-3,4-diol Chemical compound CC(O)COC1C(O)C(O)C(CO)OC1OC1C(O)C(OCCO)C(O)OC1CO RFRMMZAKBNXNHE-UHFFFAOYSA-N 0.000 claims description 3
- 108010076119 Caseins Proteins 0.000 claims description 3
- 241000196324 Embryophyta Species 0.000 claims description 3
- 241000238631 Hexapoda Species 0.000 claims description 3
- 229920001479 Hydroxyethyl methyl cellulose Polymers 0.000 claims description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 3
- 230000021736 acetylation Effects 0.000 claims description 3
- 238000006640 acetylation reaction Methods 0.000 claims description 3
- 125000003277 amino group Chemical group 0.000 claims description 3
- 210000003056 antler Anatomy 0.000 claims description 3
- 230000001580 bacterial effect Effects 0.000 claims description 3
- 230000021235 carbamoylation Effects 0.000 claims description 3
- 150000001735 carboxylic acids Chemical class 0.000 claims description 3
- 239000005018 casein Substances 0.000 claims description 3
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 claims description 3
- 235000021240 caseins Nutrition 0.000 claims description 3
- 238000004113 cell culture Methods 0.000 claims description 3
- 210000002808 connective tissue Anatomy 0.000 claims description 3
- 229960002086 dextran Drugs 0.000 claims description 3
- 230000002439 hemostatic effect Effects 0.000 claims description 3
- 230000007062 hydrolysis Effects 0.000 claims description 3
- 238000006460 hydrolysis reaction Methods 0.000 claims description 3
- 230000002163 immunogen Effects 0.000 claims description 3
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 claims description 3
- FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- 238000005932 reductive alkylation reaction Methods 0.000 claims description 3
- 239000003894 surgical glue Substances 0.000 claims description 3
- 125000003396 thiol group Chemical group [H]S* 0.000 claims description 3
- 102000011632 Caseins Human genes 0.000 claims description 2
- 210000003284 horn Anatomy 0.000 claims description 2
- 210000000987 immune system Anatomy 0.000 claims description 2
- 210000003491 skin Anatomy 0.000 claims description 2
- 229920002678 cellulose Polymers 0.000 claims 4
- 239000001913 cellulose Substances 0.000 claims 4
- 150000002513 isocyanates Chemical class 0.000 claims 4
- 229920002472 Starch Polymers 0.000 claims 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 2
- 239000008107 starch Substances 0.000 claims 2
- 235000019698 starch Nutrition 0.000 claims 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 claims 1
- NBBJYMSMWIIQGU-UHFFFAOYSA-N Propionic aldehyde Chemical compound CCC=O NBBJYMSMWIIQGU-UHFFFAOYSA-N 0.000 claims 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims 1
- 238000001647 drug administration Methods 0.000 claims 1
- LFKYBJLFJOOKAE-UHFFFAOYSA-N imidazol-2-ylidenemethanone Chemical compound O=C=C1N=CC=N1 LFKYBJLFJOOKAE-UHFFFAOYSA-N 0.000 claims 1
- OKXGHXHZNCJMSV-UHFFFAOYSA-N nitro phenyl carbonate Chemical compound [O-][N+](=O)OC(=O)OC1=CC=CC=C1 OKXGHXHZNCJMSV-UHFFFAOYSA-N 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229940088598 enzyme Drugs 0.000 description 295
- 238000006243 chemical reaction Methods 0.000 description 90
- 239000000499 gel Substances 0.000 description 90
- 230000000694 effects Effects 0.000 description 65
- 239000000017 hydrogel Substances 0.000 description 60
- 239000000243 solution Substances 0.000 description 59
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 26
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 26
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 26
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 24
- 238000001879 gelation Methods 0.000 description 24
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 22
- 238000009792 diffusion process Methods 0.000 description 16
- 239000000565 sealant Substances 0.000 description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- 239000011734 sodium Substances 0.000 description 15
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 14
- 239000004472 Lysine Substances 0.000 description 14
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 14
- 239000004471 Glycine Substances 0.000 description 13
- 238000004458 analytical method Methods 0.000 description 13
- 238000003556 assay Methods 0.000 description 13
- 230000035484 reaction time Effects 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- 239000003550 marker Substances 0.000 description 12
- 230000002829 reductive effect Effects 0.000 description 12
- 239000004202 carbamide Substances 0.000 description 11
- 238000010828 elution Methods 0.000 description 11
- 238000009826 distribution Methods 0.000 description 10
- 239000000523 sample Substances 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- 150000001412 amines Chemical class 0.000 description 9
- 239000011324 bead Substances 0.000 description 9
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 9
- 108090001008 Avidin Proteins 0.000 description 8
- 229920002684 Sepharose Polymers 0.000 description 8
- 230000007423 decrease Effects 0.000 description 8
- 230000000670 limiting effect Effects 0.000 description 8
- 239000011780 sodium chloride Substances 0.000 description 8
- 239000001509 sodium citrate Substances 0.000 description 8
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 8
- NHJVRSWLHSJWIN-UHFFFAOYSA-N 2,4,6-trinitrobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O NHJVRSWLHSJWIN-UHFFFAOYSA-N 0.000 description 7
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 7
- 238000013459 approach Methods 0.000 description 7
- 230000006378 damage Effects 0.000 description 7
- 238000010438 heat treatment Methods 0.000 description 7
- 102000004196 processed proteins & peptides Human genes 0.000 description 7
- 239000000376 reactant Substances 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 6
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 6
- 108010090804 Streptavidin Proteins 0.000 description 6
- 239000001110 calcium chloride Substances 0.000 description 6
- 229910001628 calcium chloride Inorganic materials 0.000 description 6
- 235000011148 calcium chloride Nutrition 0.000 description 6
- 239000003638 chemical reducing agent Substances 0.000 description 6
- 239000000470 constituent Substances 0.000 description 6
- 230000001419 dependent effect Effects 0.000 description 6
- 230000007689 endotoxicity Effects 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 238000009864 tensile test Methods 0.000 description 6
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 5
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 5
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical class ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 5
- 241001662443 Phemeranthus parviflorus Species 0.000 description 5
- 239000012620 biological material Substances 0.000 description 5
- 210000001124 body fluid Anatomy 0.000 description 5
- 238000001962 electrophoresis Methods 0.000 description 5
- 230000009881 electrostatic interaction Effects 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 238000004255 ion exchange chromatography Methods 0.000 description 5
- 238000011068 loading method Methods 0.000 description 5
- 229920001184 polypeptide Polymers 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- 239000007974 sodium acetate buffer Substances 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 4
- 239000004971 Cross linker Substances 0.000 description 4
- 108010068370 Glutens Proteins 0.000 description 4
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 239000000853 adhesive Substances 0.000 description 4
- 230000001070 adhesive effect Effects 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 230000001588 bifunctional effect Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 150000001720 carbohydrates Chemical class 0.000 description 4
- 235000014633 carbohydrates Nutrition 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 230000001276 controlling effect Effects 0.000 description 4
- 230000008878 coupling Effects 0.000 description 4
- 238000010168 coupling process Methods 0.000 description 4
- 238000005859 coupling reaction Methods 0.000 description 4
- 238000012377 drug delivery Methods 0.000 description 4
- 230000009977 dual effect Effects 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 229920002401 polyacrylamide Polymers 0.000 description 4
- 150000003254 radicals Chemical class 0.000 description 4
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 3
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 239000007995 HEPES buffer Substances 0.000 description 3
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 3
- 229920000881 Modified starch Polymers 0.000 description 3
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 3
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 3
- 108700039882 Protein Glutamine gamma Glutamyltransferase 2 Proteins 0.000 description 3
- 102100038095 Protein-glutamine gamma-glutamyltransferase 2 Human genes 0.000 description 3
- 108090000631 Trypsin Proteins 0.000 description 3
- 102000004142 Trypsin Human genes 0.000 description 3
- 206010052428 Wound Diseases 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 229940030225 antihemorrhagics Drugs 0.000 description 3
- 239000010839 body fluid Substances 0.000 description 3
- 238000006555 catalytic reaction Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000023597 hemostasis Effects 0.000 description 3
- 230000009851 immunogenic response Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000004949 mass spectrometry Methods 0.000 description 3
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 3
- 235000019426 modified starch Nutrition 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 150000007965 phenolic acids Chemical class 0.000 description 3
- 150000002989 phenols Chemical class 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000006722 reduction reaction Methods 0.000 description 3
- 230000036555 skin type Effects 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 230000007704 transition Effects 0.000 description 3
- 239000012588 trypsin Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 2
- 229920002683 Glycosaminoglycan Polymers 0.000 description 2
- 101001001272 Homo sapiens Prostatic acid phosphatase Proteins 0.000 description 2
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 2
- LFVLUOAHQIVABZ-UHFFFAOYSA-N Iodofenphos Chemical compound COP(=S)(OC)OC1=CC(Cl)=C(I)C=C1Cl LFVLUOAHQIVABZ-UHFFFAOYSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 102000016943 Muramidase Human genes 0.000 description 2
- 108010014251 Muramidase Proteins 0.000 description 2
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 2
- 239000008118 PEG 6000 Substances 0.000 description 2
- 229920005439 Perspex® Polymers 0.000 description 2
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 239000004809 Teflon Substances 0.000 description 2
- 229920006362 Teflon® Polymers 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- UGXQOOQUZRUVSS-ZZXKWVIFSA-N [5-[3,5-dihydroxy-2-(1,3,4-trihydroxy-5-oxopentan-2-yl)oxyoxan-4-yl]oxy-3,4-dihydroxyoxolan-2-yl]methyl (e)-3-(4-hydroxyphenyl)prop-2-enoate Chemical compound OC1C(OC(CO)C(O)C(O)C=O)OCC(O)C1OC1C(O)C(O)C(COC(=O)\C=C\C=2C=CC(O)=CC=2)O1 UGXQOOQUZRUVSS-ZZXKWVIFSA-N 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000003872 anastomosis Effects 0.000 description 2
- 229920000617 arabinoxylan Polymers 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000000227 bioadhesive Substances 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 238000007413 biotinylation Methods 0.000 description 2
- 230000006287 biotinylation Effects 0.000 description 2
- 230000023555 blood coagulation Effects 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 238000011088 calibration curve Methods 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 210000000038 chest Anatomy 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 239000007979 citrate buffer Substances 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- XLJMAIOERFSOGZ-UHFFFAOYSA-M cyanate Chemical compound [O-]C#N XLJMAIOERFSOGZ-UHFFFAOYSA-M 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 2
- 230000009144 enzymatic modification Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000002874 hemostatic agent Substances 0.000 description 2
- 239000000416 hydrocolloid Substances 0.000 description 2
- 229960002591 hydroxyproline Drugs 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 229960000274 lysozyme Drugs 0.000 description 2
- 235000010335 lysozyme Nutrition 0.000 description 2
- 239000004325 lysozyme Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 108010004563 mussel adhesive protein Proteins 0.000 description 2
- 239000001814 pectin Substances 0.000 description 2
- 235000010987 pectin Nutrition 0.000 description 2
- 229920001277 pectin Polymers 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 235000009048 phenolic acids Nutrition 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 239000004926 polymethyl methacrylate Substances 0.000 description 2
- 235000015277 pork Nutrition 0.000 description 2
- 230000036316 preload Effects 0.000 description 2
- 150000003141 primary amines Chemical group 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 150000004053 quinones Chemical class 0.000 description 2
- 239000011535 reaction buffer Substances 0.000 description 2
- 210000000664 rectum Anatomy 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000002787 reinforcement Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 239000012812 sealant material Substances 0.000 description 2
- 238000001542 size-exclusion chromatography Methods 0.000 description 2
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229940014800 succinic anhydride Drugs 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 2
- DZGWFCGJZKJUFP-UHFFFAOYSA-N tyramine Chemical compound NCCC1=CC=C(O)C=C1 DZGWFCGJZKJUFP-UHFFFAOYSA-N 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 229920003169 water-soluble polymer Polymers 0.000 description 2
- SXGZJKUKBWWHRA-UHFFFAOYSA-N 2-(N-morpholiniumyl)ethanesulfonate Chemical compound [O-]S(=O)(=O)CC[NH+]1CCOCC1 SXGZJKUKBWWHRA-UHFFFAOYSA-N 0.000 description 1
- OZDAOHVKBFBBMZ-UHFFFAOYSA-N 2-aminopentanedioic acid;hydrate Chemical compound O.OC(=O)C(N)CCC(O)=O OZDAOHVKBFBBMZ-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 206010000050 Abdominal adhesions Diseases 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 230000005653 Brownian motion process Effects 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229920002567 Chondroitin Polymers 0.000 description 1
- 229920001651 Cyanoacrylate Polymers 0.000 description 1
- 241000252233 Cyprinus carpio Species 0.000 description 1
- 229920002271 DEAE-Sepharose Polymers 0.000 description 1
- 241001269524 Dura Species 0.000 description 1
- 108010071289 Factor XIII Proteins 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 241000276438 Gadus morhua Species 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 229920001612 Hydroxyethyl starch Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical group OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 208000034693 Laceration Diseases 0.000 description 1
- 108010060630 Lactoglobulins Proteins 0.000 description 1
- 102000008192 Lactoglobulins Human genes 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102000036675 Myoglobin Human genes 0.000 description 1
- 108010062374 Myoglobin Proteins 0.000 description 1
- 108091006006 PEGylated Proteins Proteins 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 101710123874 Protein-glutamine gamma-glutamyltransferase Proteins 0.000 description 1
- 239000012614 Q-Sepharose Substances 0.000 description 1
- 208000002847 Surgical Wound Diseases 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 241000656145 Thyrsites atun Species 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 241000218215 Urticaceae Species 0.000 description 1
- ZAFQHMFHEMVQEB-UHFFFAOYSA-N acetonitrile 2,2,2-trifluoroacetic acid Chemical compound CC#N.OC(=O)C(F)(F)F.OC(=O)C(F)(F)F ZAFQHMFHEMVQEB-UHFFFAOYSA-N 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000003592 biomimetic effect Effects 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 238000005537 brownian motion Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 238000005266 casting Methods 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 229920003086 cellulose ether Polymers 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- NCEXYHBECQHGNR-UHFFFAOYSA-N chembl421 Chemical compound C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 1
- 238000010382 chemical cross-linking Methods 0.000 description 1
- 238000002144 chemical decomposition reaction Methods 0.000 description 1
- DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001427 coherent effect Effects 0.000 description 1
- 238000007398 colorimetric assay Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000011243 crosslinked material Substances 0.000 description 1
- NLCKLZIHJQEMCU-UHFFFAOYSA-N cyano prop-2-enoate Chemical class C=CC(=O)OC#N NLCKLZIHJQEMCU-UHFFFAOYSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 238000011026 diafiltration Methods 0.000 description 1
- 230000009699 differential effect Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000009088 enzymatic function Effects 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- 229940012444 factor xiii Drugs 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 108010073651 fibrinmonomer Proteins 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000011902 gastrointestinal surgery Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 1
- 235000021312 gluten Nutrition 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 230000000025 haemostatic effect Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- 229940050526 hydroxyethylstarch Drugs 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 101150051171 mtgA gene Proteins 0.000 description 1
- 239000006225 natural substrate Substances 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000010399 physical interaction Effects 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920000307 polymer substrate Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 125000004151 quinonyl group Chemical group 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 229920006298 saran Polymers 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 238000000935 solvent evaporation Methods 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000006276 transfer reaction Methods 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 229960003732 tyramine Drugs 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1025—Acyltransferases (2.3)
- C12N9/1029—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
- A61L24/08—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
- A61L24/10—Polypeptides; Proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/20—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1025—Acyltransferases (2.3)
- C12N9/104—Aminoacyltransferases (2.3.2)
- C12N9/1044—Protein-glutamine gamma-glutamyltransferase (2.3.2.13), i.e. transglutaminase or factor XIII
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/45—Transferases (2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L17/00—Materials for surgical sutures or for ligaturing blood vessels ; Materials for prostheses or catheters
- A61L17/06—At least partially resorbable materials
- A61L17/08—At least partially resorbable materials of animal origin, e.g. catgut, collagen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/04—Materials for stopping bleeding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y203/00—Acyltransferases (2.3)
- C12Y203/02—Aminoacyltransferases (2.3.2)
- C12Y203/02013—Protein-glutamine gamma-glutamyltransferase (2.3.2.13), i.e. transglutaminase or factor XIII
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Transplantation (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Dermatology (AREA)
- Surgery (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Materials For Medical Uses (AREA)
- Medicinal Preparation (AREA)
- Enzymes And Modification Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Processes Of Treating Macromolecular Substances (AREA)
Claims (25)
1. Tværbundet matrix, der omfatter en substratpolymer tværbundet af et modificeret enzymmolekyle, hvilket modificeret enzymmolekyle har en modificering, der ændrer et opfattet volumen af enzymmolekyleme i det tværbundne matrix, mens matrixen dannes ved tværbinding af polymeren.
2. Matrix ifølge krav 1, hvor det modificerede enzymmolekyle har en modificering, der: a) øger en faktisk størrelse af det modificerede enzymmolekyle; eller b) øger et hydrodynamisk volumen af det modificerede enzymmolekyle; eller c) modificerer en elektrostatisk ladning af det modificerede enzymmolekyle til at være det modsatte tegn af en nettoladning af substratpolymeme ved at ændre det modificerede enzyms isoelektriske punkt sammenlignet med umodificeret enzym.
3. Matrix ifølge krav 2 c), hvor modificeringen enten er af enzymets ε-aminogruppe af lysiner ved en fremgangsmåde udvalgt fra gruppen bestående af succinylering, acetylering, carbamylering, reduktiv alkylering og behandling med maleinanhydrid eller er af én eller flere sidekæder, der indeholder carboxylsyrer af enzymet, for at formindske antallet af negative ladninger.
4. Matrix ifølge et hvilket som helst af kravene 2 eller 3, hvor modificeringen omfatter kovalent eller ikke-kovalent binding af mindst ét molekyle eller en del til det modificerede enzymmolekyle.
5. Matrix ifølge krav 4, hvor modificeringen omfatter kovalent binding af et modificerende molekyle til det modificerede enzymmolekyle.
6. Matrix ifølge krav 5, hvor det modificerende molekyle omfatter en bærer eller polymer.
7. Matrix ifølge krav 6, hvor polymeren omfatter en syntetisk polymer, en cellulosepolymer, et protein eller et polysaccharid.
8. Matrix ifølge krav 7, hvor a) cellulosepolymeren omfatter én eller flere af carboxymethylcellulose, hydroxypropylmethylcellulose, hydroxyethylcellulose eller methylcellulose; eller b) polysaccharidet omfatter én eller flere af dextran, chondroitinsulfat, dermatansulfat, keratansulfat, heparin, heparansulfat, hyaluronsyre eller en stivelse eller c) det modificerende molekyle omfatter polyethylenglycol (PEG).
9. Matrix ifølge krav 8, hvor PEG omfatter aktiveret PEG, og hvor det aktiverede PEG omfatter én eller flere af methoxy PEG (mPEG), mPEG-NHS, succinimidylestere af mPEG, mPEG-glutarat-NHS, mPEG-valerat-NHS, mPEG-carbonat-NHS, mPEG- carboxymethyl-NHS, mPEG-propionat-NHS, mPEG-carboxypentyl-NHS, mPEG- nitrophenylcarbonat, mPEG-propylaldehyd, mPEG-tosylat, mPEG- carbonylimidazol, mPEG-isocyanat, mPEG-epoxid eller en kombination deraf.
10. Matrix ifølge krav 9, hvor a) det aktiverede PEG reagerer med amingrupper eller thiolgrupper på enzymet; og/eller b) molforholdet mellem det aktiverede PEG og lysinrester fra det aktiverede enzym er i et forhold på fra 0,5 til 25; og/eller c) det aktiverede PEG er monofunktionelt, heterobifunktionelt, homobifunktionelt eller multifunktionelt; og/eller d) det aktiverede PEG er forgrenede PEG’er eller PEG’er med flere arme; og/eller e) det aktiverede PEG har en størrelse, der ligger i området fra 1.000 dalton til 40.000 dalton.
11. Matrix ifølge et hvilket som helst af de ovenstående krav, der endvidere omfatter en co-polymer, der ikke er kovalent bundet til enzymet eller til substratpolymeren.
12. Matrix ifølge krav 11, hvor co-polymeren omfatter et polysaccharid eller en cellulosepolymer.
13. Matrix ifølge krav 12, hvor a) polysaccharidet omfatter dextran, chondroitinsulfat, dermatansulfat, keratansulfat, heparin, heparansulfat, hyaluronsyre eller en stivelse eller b) cellulosepolymeren omfatter carboxymethylcellulose, hydroxypropylmethylcellulose, hydroxyethylcellulose eller methylcellulose.
14. Matrix ifølge et hvilket som helst af de ovenstående krav, hvor det modificerede enzymmolekyle er modificeret ved tværbinding af det modificerede enzymmolekyle til et antal andre enzymmolekyler for at danne en samling af et antal af tværbundne enzymmolekyler.
15. Fremgangsmåde til styring af dannelsen af et matrix, der omfatter: modificering af et enzymmolekyle med en modificering, der ændrer et opfattet volumen af enzymmolekyleme i det tværbundne matrix, når matrixen dannes; blanding af det modificerede enzymmolekyle med mindst ét substratpolymer, der er et substrat af det modificerede enzymmolekyle; og dannelse af matrixen ved tværbinding af mindst ét substratpolymer via det modificerede enzymmolekyle, hvor dannelsen af matrixen er mindst delvist styret af modificeringen af enzymmolekylet.
16. Fremgangsmåde ifølge krav 15, hvor det modificerede enzymmolekyle og mindst den ene substratpolymer er blandet i opløsning, således at modificeringen styrer omfanget af tværbinding af mindst den ene substratpolymer, mens en viskositet af opløsningen øges; og eventuelt omfatter modificeringen af PEGylering af enzymet ved et pH, der ligger i området fra 7 til 9.
17. Fremgangsmåde eller matrix ifølge et hvilket som helst af de ovenstående krav, hvor mindst den ene substratpolymer omfatter a) en substratpolymer udvalgt lfa gruppen bestående af en naturligt tværbunden polymer, en delvist denatureret polymer, der er tværbundet af det modificerede enzym og en modificeret polymer, der omfatter en funktionel gruppe eller et peptid, der er tværbundet af det modificerede enzym; og/eller b) gelatine, collagen, casein eller albumin, og hvor det modificerede enzymmolekyle omfatter en modificeret transglutaminase og/eller et modificeret oxidativt enzym; og/eller c) hvor gelatinen er udvalgt fra gruppen bestående af gelatine opnået ved delvis hydrolyse af dyrevæv eller collagen opnået fra dyrevæv, hvor dyrevævet er udvalgt fra gruppen bestående af dyrehud, bindevæv, gevir, horn, knogler, fiskeskæl, og en rekombinant gelatine fremstillet ved anvendelse af bakterielle, gær-, dyre-, insekt- eller plantesystemer eller en hvilken som helst type af cellekultur eller en hvilken som helst kombination deraf.
18. Fremgangsmåde eller matrix ifølge krav 17, hvor a) den modificerede transglutaminase omfatter modificeret mikrobiel transglutaminase eller b) hvor det modificerede oxidative enzym omfatter én eller flere af tyrosinase, laccase eller peroxidase.
19. Fremgangsmåde eller matrix ifølge et hvilket som helst af de ovenstående krav, hvor enzymmolekylet er modificeret ved pegylering, og hvor pegyleringen tilvejebringer immunogen maskering ved at maskere enzymmolekylet ffa et immunsystem i en dyrevært, der modtager matrixen.
20. Hæmostatisk middel eller kirurgisk forseglingsmiddel, der omfatter et matrix som defineret ifølge et hvilket som helst af de ovenstående krav.
21. Sammensætning til anvendelse til lukning af et sår, der omfatter et matrix som defineret ifølge et hvilket som helst af de ovenstående krav.
22. Sammensætning ifølge krav 21 til anvendelse ved forsegling af sutur eller hæfteklammelinjer i et væv.
23. Sammensætning til en excipiens til anvendelse i et lokaliseret lægemiddelindgivelse, der omfatter et matrix som defineret ifølge et hvilket som helst af de ovenstående krav.
24. Sammensætning til anvendelse i vævsengineering omfattende et matrix som defineret ifølge et hvilket som helst af de ovenstående krav, der er tilpasset som et injicerbart støttemateriale.
25. Fremgangsmåde til modificering af en sammensætning, der omfatter: tilvejebringelse af et modificeret enzym, der har en tværbunden funktionel gruppe, og et protein, der har mindst én del tværbunden af det modificerede enzym; blanding af det modificerede enzym og protein, hvor det modificerede enzym tværbinder proteinet og ligeledes tværbindes til proteinet via den tværbundne funktionsgruppe.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28936809P | 2009-12-22 | 2009-12-22 | |
| PCT/IB2010/056008 WO2011077388A1 (en) | 2009-12-22 | 2010-12-22 | Modification of enzymatic crosslinkers for controlling properties of crosslinked matrices |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2515957T3 true DK2515957T3 (da) | 2015-11-09 |
Family
ID=44246887
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK10814706.7T DK2515957T3 (da) | 2009-12-22 | 2010-12-22 | Ændring af enzymatiske tværbindere for styring af egenskaber ved tværbundne matrixer |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US9066991B2 (da) |
| EP (2) | EP2515957B1 (da) |
| JP (1) | JP5796860B2 (da) |
| CN (1) | CN102711853B (da) |
| AU (1) | AU2010334412B2 (da) |
| BR (1) | BR112012015029A2 (da) |
| CA (1) | CA2782863A1 (da) |
| DK (1) | DK2515957T3 (da) |
| ES (1) | ES2551388T3 (da) |
| IL (1) | IL220325A (da) |
| WO (1) | WO2011077388A1 (da) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2111239B1 (en) * | 2006-12-15 | 2013-03-06 | Lifebond Ltd. | Gelatin-transglutaminase hemostatic dressings and sealants |
| ES2551388T3 (es) | 2009-12-22 | 2015-11-18 | Lifebond Ltd | Modificación de agentes de entrecruzamiento enzimáticos para controlar las propiedades de las matrices entrecruzadas |
| AU2011287215B2 (en) | 2010-08-05 | 2015-09-10 | Lifebond Ltd. | Dry composition wound dressings and adhesives |
| EP2776052B1 (en) * | 2011-11-02 | 2017-06-14 | Halscion, Inc. | Methods and compositions for wound treatment |
| CN104144950B (zh) * | 2011-12-19 | 2017-09-05 | 迪乐方有限责任公司 | 含有重复的二糖单元的非抗凝的葡糖胺聚糖及其医药用途 |
| CN102824654B (zh) * | 2012-09-11 | 2014-07-02 | 武汉理工大学 | 一种采用双生物酶修饰的明胶与壳聚糖共混生物材料及其制备方法与应用 |
| WO2014067933A1 (en) * | 2012-10-31 | 2014-05-08 | C-Lecta Gmbh | Bioactive carrier preparation for enhanced safety in care products and food |
| WO2015048355A1 (en) * | 2013-09-26 | 2015-04-02 | Northwestern University | Poly(ethylene glycol) cross-linking of soft materials to tailor viscoelastic properties for bioprinting |
| CN104018244B (zh) * | 2014-05-30 | 2016-05-04 | 江南大学 | 一种酶处理结合静电纺制备复合蛋白纤维的方法 |
| WO2016022807A1 (en) | 2014-08-08 | 2016-02-11 | The Brigham And Women's Hospital, Inc. | Elastic biopolymer and use as a tissue adhesive |
| US10723783B2 (en) | 2015-03-19 | 2020-07-28 | The Brigham And Women's Hospital, Inc. | Polypeptide compositions and methods of using the same |
| US11058800B2 (en) | 2016-02-08 | 2021-07-13 | Massachusetts Eye And Ear Infirmary | Bioadhesive for corneal repair |
| AU2017220193B2 (en) * | 2016-02-19 | 2021-10-14 | Just, Inc. | Functional mung bean-derived compositions |
| CN105754968B (zh) * | 2016-04-29 | 2020-02-21 | 北京化工大学 | 一种改性脂肪酶及其制备方法 |
| EP3272864A1 (en) * | 2016-07-20 | 2018-01-24 | Paul Scherrer Institut | Solid-phase immobilization of microbial transglutaminase mtg on microbeads for protein conjugation |
| CA3055985A1 (en) | 2017-03-22 | 2018-09-27 | Genentech, Inc. | Hydrogel cross-linked hyaluronic acid prodrug compositions and methods |
| CN111432853A (zh) * | 2017-10-04 | 2020-07-17 | 百奥诚智有限公司 | 交联的蛋白质泡沫及其使用多用途细胞支架的方法 |
| CN109876187B (zh) * | 2017-12-06 | 2021-10-01 | 西北大学 | 球状蛋白作致孔剂的组织工程软骨修复支架及其制备方法 |
| JP6960862B2 (ja) * | 2018-01-15 | 2021-11-05 | 日本バイリーン株式会社 | ゼラチン溶液と該ゼラチン溶液からなる紡糸液、および、該紡糸液を用いた繊維集合体の製造方法と該ゼラチン溶液を用いたフィルムならびに複合体の製造方法 |
| CN108434510B (zh) * | 2018-05-23 | 2021-03-02 | 宁波宝亭生物科技有限公司 | 一种改性淀粉止血微球的制备方法 |
| CN109295137B (zh) * | 2018-10-17 | 2020-11-06 | 四川大学 | 一种多步连续酶催化微纤维胶原交联改性的方法 |
| CN112494710B (zh) * | 2019-09-16 | 2021-12-14 | 天津大学 | 一种转谷氨酰胺酶促交联的双网络粘合剂及其制备方法 |
| CN110684211B (zh) * | 2019-10-14 | 2022-07-12 | 宁夏妙朗生物科技有限公司 | 制备抵抗α-葡萄糖苷酶水解的交联右旋糖苷凝胶的方法 |
| TWI742571B (zh) * | 2020-03-18 | 2021-10-11 | 美商威斯頓股份有限公司 | 生物材料及其用於促進組織再生的用途 |
| CN111849960B (zh) * | 2020-07-20 | 2023-05-23 | 苏州大学 | 一种交联酶的制备方法 |
| EP3957338A1 (en) * | 2020-08-20 | 2022-02-23 | Aobakasei Kabushiki Kaisha | Liquid medical material |
| CN113244437A (zh) * | 2021-06-15 | 2021-08-13 | 福州大学 | 一种仿生多功能复合海绵敷料的制备方法与应用 |
| CN117924740A (zh) * | 2022-10-14 | 2024-04-26 | 中国科学院苏州纳米技术与纳米仿生研究所 | 一种胶原水凝胶及其制备方法和应用 |
Family Cites Families (246)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA896965A (en) | 1972-04-04 | De Boer Rintje | Process for producing a dry gelatin product | |
| US1873580A (en) | 1932-08-23 | Dustries limited | ||
| US2719145A (en) | 1955-09-27 | Process for effecting complex | ||
| US1394654A (en) | 1920-12-27 | 1921-10-25 | Donald K Tressler | Manufacture of liquid glue |
| US1844679A (en) | 1925-12-07 | 1932-02-09 | Glue Res Corp | Glue solution and process of manufacturing same |
| US1950483A (en) | 1931-07-13 | 1934-03-13 | Swift & Co | Preparation of glue and the product thereof |
| US2048499A (en) | 1934-04-07 | 1936-07-21 | Deutsche Hydrierwerke Ag | Gelatine solutions |
| US2166074A (en) | 1937-04-09 | 1939-07-11 | Sharp & Dohme Inc | Gelatinous colloids |
| US2126305A (en) | 1937-06-23 | 1938-08-09 | Eastman Kodak Co | Dispersion of gelatin |
| US2417713A (en) | 1940-03-19 | 1947-03-18 | Ilford Ltd | Production of gelatin layers |
| US2398004A (en) | 1943-07-20 | 1946-04-09 | Eastman Kodak Co | Controlling the isoelectric point of gelatin |
| US2558065A (en) | 1949-05-03 | 1951-06-26 | Linwood F Tice | Method of preparing solutions of gelatin in polyhydric alcohols |
| US2658001A (en) | 1950-09-26 | 1953-11-03 | Swift & Co | Liquid glue composition |
| US2803548A (en) | 1955-02-07 | 1957-08-20 | Louis Milani Foods Inc | Method of making gelatin-containing food preparations which dissolve at room temperature and gel at room temperature |
| US3220845A (en) | 1963-04-10 | 1965-11-30 | Keuffel & Esser Co | Epoxy resin impregnated photo base and method of preparation |
| US3600482A (en) | 1970-01-15 | 1971-08-17 | Monsanto Res Corp | Method of forming a mat of fibrous gelatin |
| US3939001A (en) | 1973-06-08 | 1976-02-17 | General Foods Corporation | Spoonable frozen gelatin dessert concentrate |
| US3988479A (en) | 1975-03-26 | 1976-10-26 | Stephan John T | Gelled proteinaceous fish bait and process of preparing same |
| US4188373A (en) | 1976-02-26 | 1980-02-12 | Cooper Laboratories, Inc. | Clear, water-miscible, liquid pharmaceutical vehicles and compositions which gel at body temperature for drug delivery to mucous membranes |
| DE2612726C3 (de) | 1976-03-25 | 1979-03-15 | Boehringer Mannheim Gmbh, 6800 Mannheim | Stabilisierte Urease |
| JPS5832576B2 (ja) | 1976-10-28 | 1983-07-14 | 協和醗酵工業株式会社 | ゼラチンの改質法 |
| SE415804B (sv) | 1978-06-21 | 1980-10-27 | Nils Johannes Baecklund | Sett att medelst rontgenstralning meta halten eller mengden av ett forutbestemt grundemne i ett prov, samt anordning for utforande av settet |
| US4426443A (en) | 1981-08-27 | 1984-01-17 | Dynagel, Incorporated | Preparation of hydrolyzed collagen-containing products from non-gelled, liquid hydrolyzed collagen concentrate and gelled products prepared therefrom |
| US4527906A (en) | 1982-12-27 | 1985-07-09 | Venda Jezbera | Digital menstrual cycle indicator |
| US4478822A (en) | 1983-05-16 | 1984-10-23 | Merck & Co., Inc. | Drug delivery system utilizing thermosetting gels |
| CA1202904A (en) | 1983-11-21 | 1986-04-08 | Brian G. Sparkes | Chitosan based wound dressing materials |
| WO1987000196A1 (en) | 1985-07-09 | 1987-01-15 | Quadrant Bioresources Limited | Protection of proteins and the like |
| US4711848A (en) | 1984-03-14 | 1987-12-08 | Zymogenetics, Inc. | Site specific mutagenesis in alpha-1-antitrypsin |
| US4605513A (en) | 1984-08-08 | 1986-08-12 | Eli Lilly And Company | Process for inhibiting peptide carbamylation |
| JPS61240963A (ja) | 1985-04-18 | 1986-10-27 | ユニチカ株式会社 | 創傷被覆保護材 |
| FR2586030B1 (fr) | 1985-08-07 | 1987-12-18 | Rousselot Cie | Gelatine a proprietes ameliorees et son procede de preparation par pelliculage avec une gelatine hydrolysee |
| JPS6323670A (ja) | 1986-04-25 | 1988-01-30 | バイオ−ポリマ−ズ インコ−ポレ−テツド | 接着・被覆組成物とその使用方法 |
| EP0302953A1 (de) | 1987-08-11 | 1989-02-15 | Deutsche Gelatine-Fabriken Stoess AG | Verfahren zur Herrstellung von Formkörpern aus Kollagen und Kollagenabbauprodukten |
| DE3726963A1 (de) | 1987-08-13 | 1989-02-23 | Stoess & Co Gelatine | Kaltwasserloesliche, instantisierte gelatine und verfahren zur herstellung derselben |
| US4952618A (en) | 1988-05-03 | 1990-08-28 | Minnesota Mining And Manufacturing Company | Hydrocolloid/adhesive composition |
| US4837379A (en) | 1988-06-02 | 1989-06-06 | Organogenesis Inc. | Fibrin-collagen tissue equivalents and methods for preparation thereof |
| GB8813161D0 (en) | 1988-06-03 | 1988-07-06 | Unilever Plc | Emulsions |
| US4948540A (en) | 1988-08-01 | 1990-08-14 | Semex Medical, Inc. | Method of preparing collagen dressing sheet material |
| JPH02255888A (ja) | 1988-11-08 | 1990-10-16 | Nippon Oil & Fats Co Ltd | 架橋ゼラチンゲル |
| US4971954A (en) | 1988-11-23 | 1990-11-20 | University Of Medicine And Dentistry Of New Jersey | Collagen-based matrices ribose cross-linked |
| JP2719166B2 (ja) * | 1989-02-02 | 1998-02-25 | 鐘紡株式会社 | 毛髪化粧料組成物 |
| US5026785A (en) | 1989-05-12 | 1991-06-25 | The United States Of America As Represented By The Department Of Health And Human Services | Avidin and streptavidin modified water-soluble polymers such as polyacrylamide, and the use thereof in the construction of soluble multivalent macromolecular conjugates |
| JPH0395109A (ja) * | 1989-09-08 | 1991-04-19 | Kanebo Ltd | 毛髪化粧料 |
| US4931501A (en) | 1989-10-20 | 1990-06-05 | Air Products And Chemicals, Inc. | Modified poly(vinyl alcohol) containing morpholinoalkylether groups |
| DE4007668A1 (de) | 1990-03-10 | 1991-09-12 | Beiersdorf Ag | Hydrogelschaeume und verfahren zu deren herstellung |
| US5209776A (en) | 1990-07-27 | 1993-05-11 | The Trustees Of Columbia University In The City Of New York | Tissue bonding and sealing composition and method of using the same |
| US5059636A (en) | 1990-11-13 | 1991-10-22 | Grenga Paul A | Tire sealant composition |
| US6117425A (en) | 1990-11-27 | 2000-09-12 | The American National Red Cross | Supplemented and unsupplemented tissue sealants, method of their production and use |
| US7196054B1 (en) | 1990-11-27 | 2007-03-27 | The American National Red Cross | Methods for treating wound tissue and forming a supplemented fibrin matrix |
| US6197325B1 (en) | 1990-11-27 | 2001-03-06 | The American National Red Cross | Supplemented and unsupplemented tissue sealants, methods of their production and use |
| US6054122A (en) | 1990-11-27 | 2000-04-25 | The American National Red Cross | Supplemented and unsupplemented tissue sealants, methods of their production and use |
| US6559119B1 (en) | 1990-11-27 | 2003-05-06 | Loyola University Of Chicago | Method of preparing a tissue sealant-treated biomedical material |
| US5480644A (en) | 1992-02-28 | 1996-01-02 | Jsf Consultants Ltd. | Use of injectable biomaterials for the repair and augmentation of the anal sphincters |
| US5573934A (en) | 1992-04-20 | 1996-11-12 | Board Of Regents, The University Of Texas System | Gels for encapsulation of biological materials |
| EP0598133B1 (en) | 1992-04-21 | 2000-03-29 | Ajinomoto Co., Inc. | Remedy for wound |
| IL105529A0 (en) | 1992-05-01 | 1993-08-18 | Amgen Inc | Collagen-containing sponges as drug delivery for proteins |
| AU678764B2 (en) | 1992-06-03 | 1997-06-12 | Case Western Reserve University | Bandage for continuous application of biologicals |
| JP3224607B2 (ja) | 1992-09-11 | 2001-11-05 | 株式会社アズウェル | 血液凝固第ｘｉｉｉ因子活性測定方法および該測定用試薬キット |
| US5433943A (en) | 1992-12-21 | 1995-07-18 | Osipow; Lloyd I. | Deodorant and/or antiperspirant compositions |
| US5549904A (en) | 1993-06-03 | 1996-08-27 | Orthogene, Inc. | Biological adhesive composition and method of promoting adhesion between tissue surfaces |
| GB9313501D0 (en) | 1993-06-30 | 1993-08-11 | Nycomed Imaging As | Improvements in or relating to polymer materials |
| US5939385A (en) | 1993-08-13 | 1999-08-17 | Zymogenetics, Inc. | Transglutaminase cross-linkable polypeptides and methods relating thereto |
| US5428014A (en) | 1993-08-13 | 1995-06-27 | Zymogenetics, Inc. | Transglutaminase cross-linkable polypeptides and methods relating thereto |
| US5487895A (en) | 1993-08-13 | 1996-01-30 | Vitaphore Corporation | Method for forming controlled release polymeric substrate |
| US5441193A (en) | 1993-09-23 | 1995-08-15 | United States Surgical Corporation | Surgical fastener applying apparatus with resilient film |
| US5503638A (en) | 1994-02-10 | 1996-04-02 | Bio-Vascular, Inc. | Soft tissue stapling buttress |
| JP3433302B2 (ja) | 1994-02-21 | 2003-08-04 | 株式会社ニチロ | 新規ゲル化素材及びその製造法並びにこれを用いたゲル化食品とその製造法 |
| US6704210B1 (en) | 1994-05-20 | 2004-03-09 | Medtronic, Inc. | Bioprothesis film strip for surgical stapler and method of attaching the same |
| JPH07328108A (ja) | 1994-06-10 | 1995-12-19 | Ajinomoto Co Inc | 生体組織接着剤及び血液凝固剤 |
| EP0777726B1 (en) | 1994-08-26 | 2006-06-07 | Novozymes A/S | Microbial transglutaminases, their production and use |
| US5931165A (en) | 1994-09-06 | 1999-08-03 | Fusion Medical Technologies, Inc. | Films having improved characteristics and methods for their preparation and use |
| JP3651003B2 (ja) | 1994-10-11 | 2005-05-25 | 味の素株式会社 | 安定化されたトランスグルタミナーゼ及びそれを含む酵素製剤 |
| FR2726571B1 (fr) | 1994-11-03 | 1997-08-08 | Izoret Georges | Colle biologique, procede de preparation et dispositif d'application pour colle biologique, et durcisseurs pour colle biologique |
| WO1996017633A1 (en) | 1994-12-07 | 1996-06-13 | The American National Red Cross | Supplemented and unsupplemented tissue sealants, methods of their production and use |
| CA2206852A1 (en) | 1994-12-07 | 1996-06-13 | Novo Nordisk A/S | Polypeptide with reduced allergenicity |
| GB9501040D0 (en) | 1995-01-19 | 1995-03-08 | Quadrant Holdings Cambridge | Dried composition |
| ATE248219T1 (de) | 1995-01-19 | 2003-09-15 | Novozymes As | Transglutaminasen aus oomyzeten |
| US7253262B2 (en) | 1995-01-19 | 2007-08-07 | Quandrant Drug Delivery Limited | Dried blood factor composition comprising trehalose |
| JP3669390B2 (ja) | 1995-02-09 | 2005-07-06 | 味の素株式会社 | バチルス属細菌由来のトランスグルタミナーゼ |
| US5900245A (en) | 1996-03-22 | 1999-05-04 | Focal, Inc. | Compliant tissue sealants |
| WO1996040791A1 (en) | 1995-06-07 | 1996-12-19 | Novo Nordisk A/S | Modification of polypeptides |
| US5702409A (en) | 1995-07-21 | 1997-12-30 | W. L. Gore & Associates, Inc. | Device and method for reinforcing surgical staples |
| US5810855A (en) | 1995-07-21 | 1998-09-22 | Gore Enterprise Holdings, Inc. | Endoscopic device and method for reinforcing surgical staples |
| SE504680C2 (sv) | 1995-09-19 | 1997-04-07 | Rekordverken Ab | Tallrik med fläkt- och kastvingar och urtag för spridning av agnar och boss från en skördetröska |
| WO1997013461A1 (en) | 1995-10-11 | 1997-04-17 | Fusion Medical Technologies, Inc. | Device and method for sealing tissue |
| JPH09122227A (ja) | 1995-10-31 | 1997-05-13 | Bio Eng Lab:Kk | 医用材料およびその製造方法 |
| US5691152A (en) | 1995-11-09 | 1997-11-25 | E. R. Squibb & Sons, Inc. | Stable avidin composition |
| US5752974A (en) | 1995-12-18 | 1998-05-19 | Collagen Corporation | Injectable or implantable biomaterials for filling or blocking lumens and voids of the body |
| US5814022A (en) | 1996-02-06 | 1998-09-29 | Plasmaseal Llc | Method and apparatus for applying tissue sealant |
| DE19604706A1 (de) | 1996-02-09 | 1997-08-14 | Merck Patent Gmbh | Vernetzungsprodukte von Aminogruppen-haltigen Biopolymeren |
| WO1997029715A1 (en) | 1996-02-20 | 1997-08-21 | Fusion Medical Technologies, Inc. | Compositions and methods for sealing tissue and preventing post-surgical adhesions |
| CZ318998A3 (cs) | 1996-04-04 | 1999-09-15 | Baxter Aktiengesellschaft | Hemostatická houba na bázi kolagenu, způsob její přípravy, kryt na ránu a kit k přípravě tohoto krytu |
| US6132765A (en) | 1996-04-12 | 2000-10-17 | Uroteq Inc. | Drug delivery via therapeutic hydrogels |
| US5834232A (en) | 1996-05-01 | 1998-11-10 | Zymogenetics, Inc. | Cross-linked gelatin gels and methods of making them |
| WO1997041899A1 (en) | 1996-05-03 | 1997-11-13 | Innogenetics N.V. | New medicaments containing gelatin cross-linked with oxidized polysaccharides |
| JP3407599B2 (ja) | 1996-07-01 | 2003-05-19 | 味の素株式会社 | 接着用酵素製剤及び接着食品の製造法 |
| US7435425B2 (en) | 2001-07-17 | 2008-10-14 | Baxter International, Inc. | Dry hemostatic compositions and methods for their preparation |
| US6063061A (en) | 1996-08-27 | 2000-05-16 | Fusion Medical Technologies, Inc. | Fragmented polymeric compositions and methods for their use |
| US7320962B2 (en) | 1996-08-27 | 2008-01-22 | Baxter International Inc. | Hemoactive compositions and methods for their manufacture and use |
| US6066325A (en) | 1996-08-27 | 2000-05-23 | Fusion Medical Technologies, Inc. | Fragmented polymeric compositions and methods for their use |
| US6706690B2 (en) | 1999-06-10 | 2004-03-16 | Baxter Healthcare Corporation | Hemoactive compositions and methods for their manufacture and use |
| ZA978537B (en) | 1996-09-23 | 1998-05-12 | Focal Inc | Polymerizable biodegradable polymers including carbonate or dioxanone linkages. |
| US5752965A (en) | 1996-10-21 | 1998-05-19 | Bio-Vascular, Inc. | Apparatus and method for producing a reinforced surgical fastener suture line |
| CA2279986A1 (en) | 1997-02-06 | 1998-08-13 | Novo Nordisk A/S | Polypeptide-polymer conjugates having added and/or removed attachment groups |
| US6371975B2 (en) | 1998-11-06 | 2002-04-16 | Neomend, Inc. | Compositions, systems, and methods for creating in situ, chemically cross-linked, mechanical barriers |
| WO1998043686A1 (en) | 1997-04-03 | 1998-10-08 | California Institute Of Technology | Enzyme-mediated modification of fibrin for tissue engineering |
| US6156330A (en) | 1997-05-14 | 2000-12-05 | Japan As Represented By Director General Of National Institute Of Sericultural And Entomological Sciences Ministry Of Agriculture, Forestry And Fisheries | Chitin beads, chitosan beads, process for preparing these beads, carrier comprising said beads, and process for preparing microsporidian spore |
| AU736784B2 (en) | 1997-06-03 | 2001-08-02 | Celltran Limited | New medicaments based on polymers composed of methacrylamide-modified gelatin |
| US6015474A (en) | 1997-06-20 | 2000-01-18 | Protein Polymer Technologies | Methods of using primer molecules for enhancing the mechanical performance of tissue adhesives and sealants |
| AU751880B2 (en) | 1997-06-25 | 2002-08-29 | Novozymes A/S | A modified polypeptide |
| ZA987019B (en) | 1997-08-06 | 1999-06-04 | Focal Inc | Hemostatic tissue sealants |
| DE19736420B4 (de) | 1997-08-21 | 2008-04-10 | The Whitaker Corp., Wilmington | Elektrischer Verbinder, Verbindergehäuse und Verfahren zum Einbringen eines elektrischen Kontaktes in ein Verbindergehäuse |
| JP3164032B2 (ja) | 1997-10-01 | 2001-05-08 | 日本電気株式会社 | 昇圧回路 |
| US6190896B1 (en) | 1997-11-14 | 2001-02-20 | Bassam M. Fraij | Active human cellular transglutaminase |
| US6762336B1 (en) | 1998-01-19 | 2004-07-13 | The American National Red Cross | Hemostatic sandwich bandage |
| EP1054998A1 (en) | 1998-01-20 | 2000-11-29 | Pericor Science, Inc. | Transglutaminase linkage of agents to tissue |
| US6136341A (en) | 1998-02-27 | 2000-10-24 | Petito; George D. | Collagen containing tissue adhesive |
| US6107401A (en) | 1998-03-26 | 2000-08-22 | Air Products And Chemicals, Inc. | Process for producing amine functional derivatives of poly (vinyl alcohol) |
| JP4137224B2 (ja) | 1998-03-31 | 2008-08-20 | 天野エンザイム株式会社 | 酵素による蛋白質の架橋法 |
| NO308763B1 (no) | 1998-04-08 | 2000-10-30 | Nutreco Aquaculture Res Ct As | FremgangsmÕte ved fremstilling av for for karnivore dyr, særlig for for oppdrettsfisk, under modifisering av proteinstruktur i ferdig formede forpelleter, -kuler og lignende forpartikler/-stykker for Õ oppnÕ formbestandighet, styrke og fasthet h |
| US6047861A (en) | 1998-04-15 | 2000-04-11 | Vir Engineering, Inc. | Two component fluid dispenser |
| WO1999057258A1 (en) * | 1998-05-01 | 1999-11-11 | The Procter & Gamble Company | Laundry detergent and/or fabric care compositions comprising a modified transferase |
| US6428978B1 (en) | 1998-05-08 | 2002-08-06 | Cohesion Technologies, Inc. | Methods for the production of gelatin and full-length triple helical collagen in recombinant cells |
| AU755486B2 (en) | 1998-05-19 | 2002-12-12 | American National Red Cross, The | Hemostatic sandwich bandage |
| US20020015724A1 (en) | 1998-08-10 | 2002-02-07 | Chunlin Yang | Collagen type i and type iii hemostatic compositions for use as a vascular sealant and wound dressing |
| DE19838189A1 (de) | 1998-08-24 | 2000-03-02 | Basf Ag | Stabile pulverförmige Vitamin- und Carotinoid-Zubereitungen und Verfahren zu deren Herstellung |
| US7241730B2 (en) | 1998-08-27 | 2007-07-10 | Universitat Zurich | Enzyme-mediated modification of fibrin for tissue engineering: fibrin formulations with peptides |
| FR2784296B1 (fr) | 1998-09-18 | 2001-01-05 | Imedex Biomateriaux | Dispositif pour la formulation et la delivrance d'un melange, notamment pour l'application chirurgicale de ce melange |
| US6461849B1 (en) * | 1998-10-13 | 2002-10-08 | Novozymes, A/S | Modified polypeptide |
| AU6078899A (en) | 1998-10-13 | 2000-05-01 | Novozymes A/S | A modified polypeptide with reduced immune response |
| US6899889B1 (en) | 1998-11-06 | 2005-05-31 | Neomend, Inc. | Biocompatible material composition adaptable to diverse therapeutic indications |
| US6454787B1 (en) | 1998-12-11 | 2002-09-24 | C. R. Bard, Inc. | Collagen hemostatic foam |
| CA2356597A1 (en) | 1998-12-28 | 2000-07-13 | Ajinomoto Co., Inc. | Process for producing transglutaminase |
| US6610043B1 (en) | 1999-08-23 | 2003-08-26 | Bistech, Inc. | Tissue volume reduction |
| WO2001015750A1 (en) | 1999-08-27 | 2001-03-08 | Department Of National Defence | Hydrogel wound dressing containing liposome-encapsulated therapeutic agent |
| CA2386422A1 (en) | 1999-10-22 | 2001-04-26 | Lif-Hlaup Ehf. Bio-Gels Pharmaceuticals Inc. | Pharmaceutical composition for treatment of mucosal epithelial ulceration and/or erosion |
| US20030035786A1 (en) | 1999-11-04 | 2003-02-20 | Medtronic, Inc. | Biological tissue adhesives, articles, and methods |
| US6992172B1 (en) | 1999-11-12 | 2006-01-31 | Fibrogen, Inc. | Recombinant gelatins |
| US6425885B1 (en) | 1999-12-20 | 2002-07-30 | Ultradent Products, Inc. | Hydraulic syringe |
| EP1267876A1 (en) | 2000-03-23 | 2003-01-02 | Merck & Co., Inc. | Thrombin inhibitors |
| US6682760B2 (en) | 2000-04-18 | 2004-01-27 | Colbar R&D Ltd. | Cross-linked collagen matrices and methods for their preparation |
| JP2001329183A (ja) | 2000-05-22 | 2001-11-27 | Yuichi Mori | ゲル化性組成物 |
| CA2385925A1 (en) | 2000-07-28 | 2002-02-14 | Maria Del Pilar Montero Garcia | Method for the production of gelatin of marine origin and product thus obtained |
| US7108876B2 (en) | 2001-01-25 | 2006-09-19 | Nutricepts, Inc. | Shaped cheese reconstruction with transglutaminase |
| US6565530B2 (en) | 2001-02-28 | 2003-05-20 | Scimed Life Systems, Inc. | Immobilizing objects in the body |
| JP4051621B2 (ja) | 2001-03-30 | 2008-02-27 | 味の素株式会社 | 接着用酵素製剤及び接着成形食品の製造方法。 |
| ATE420670T1 (de) | 2001-04-25 | 2009-01-15 | Eidgenoess Tech Hochschule | Arzneimittel freisetzende matrizen zur förderung der wundheilung |
| US6592597B2 (en) | 2001-05-07 | 2003-07-15 | Ethicon Endo-Surgery, Inc. | Adhesive for attaching buttress material to a surgical fastening device |
| CN1226974C (zh) | 2001-05-16 | 2005-11-16 | 苏珊娜·伊丽莎白·查默斯 | 伤口敷料和疗伤组合物 |
| WO2002098937A1 (en) | 2001-06-01 | 2002-12-12 | Shriners Hospital For Children | Polymer composite compositions |
| US8741335B2 (en) | 2002-06-14 | 2014-06-03 | Hemcon Medical Technologies, Inc. | Hemostatic compositions, assemblies, systems, and methods employing particulate hemostatic agents formed from hydrophilic polymer foam such as Chitosan |
| GB2377939B (en) | 2001-07-26 | 2005-04-20 | Johnson & Johnson Medical Ltd | Apertured sheet materials |
| JP2005517638A (ja) | 2001-12-04 | 2005-06-16 | ジェイ．ウールバートン クリストファー | 保存安定性のあるフィブリンシーラント |
| US8501165B2 (en) | 2001-12-12 | 2013-08-06 | Promethean Surgical Devices Llc | In situ bonds |
| US6939358B2 (en) | 2001-12-20 | 2005-09-06 | Gore Enterprise Holdings, Inc. | Apparatus and method for applying reinforcement material to a surgical stapler |
| AU2003215330B2 (en) | 2002-02-21 | 2008-03-13 | Encelle, Inc. | Immobilized bioactive hydrogel matrices as surface coatings |
| US7101695B2 (en) | 2002-03-01 | 2006-09-05 | Szu-Yi Chou | Method of producing transglutaminase having broad substrate activity |
| WO2003074004A2 (en) | 2002-03-01 | 2003-09-12 | Szu-Yi Chou | Method of producing antigens |
| ES2381185T3 (es) | 2002-03-22 | 2012-05-23 | Kuros Biosurgery Ag | Composición para aumento en el tejido duro |
| US6974592B2 (en) | 2002-04-11 | 2005-12-13 | Ocean Nutrition Canada Limited | Encapsulated agglomeration of microcapsules and method for the preparation thereof |
| US7005143B2 (en) | 2002-04-12 | 2006-02-28 | 3M Innovative Properties Company | Gel materials, medical articles, and methods |
| US7377928B2 (en) | 2002-04-15 | 2008-05-27 | Cook Biotech Incorporated | Apparatus and method for producing a reinforced surgical staple line |
| JP4575152B2 (ja) | 2002-06-11 | 2010-11-04 | セルトリックス・エービー | 多孔性ゼラチン材料、ゼラチン構造、その調製方法およびその使用 |
| US20070082023A1 (en) | 2002-06-14 | 2007-04-12 | Hemcon Medical Technologies, Inc. | Supple tissue dressing assemblies, systems, and methods formed from hydrophilic polymer sponge structures such as chitosan |
| US20040106344A1 (en) | 2002-06-28 | 2004-06-03 | Looney Dwayne Lee | Hemostatic wound dressings containing proteinaceous polymers |
| US6773156B2 (en) | 2002-07-10 | 2004-08-10 | Tah Industries, Inc. | Method and apparatus for reducing fluid streaking in a motionless mixer |
| AU2002950340A0 (en) | 2002-07-23 | 2002-09-12 | Commonwealth Scientific And Industrial Research Organisation | Biodegradable polyurethane/urea compositions |
| WO2004014969A1 (en) | 2002-08-09 | 2004-02-19 | Ottawa Health Research Institute | Bio-synthetic matrix and uses thereof |
| DE10261126A1 (de) | 2002-08-13 | 2004-03-04 | Aventis Behring Gmbh | Lagerungsstabile, flüssige Fibrinogen-Formulierung |
| AU2003270401B2 (en) | 2002-09-10 | 2008-03-13 | American National Red Cross | Hemostatic dressing |
| WO2004028274A1 (ja) | 2002-09-26 | 2004-04-08 | Ajinomoto Co., Inc. | 酵素製剤及びそれを用いる食品の製造法 |
| US7138373B2 (en) | 2002-09-26 | 2006-11-21 | University Of Maryland, Baltimore County | Polysaccharide-based polymers and methods of making the same |
| WO2004028404A2 (en) | 2002-09-30 | 2004-04-08 | Fibrogen, Inc. | Dry tissue sealant compositions |
| GB2393656B (en) | 2002-10-01 | 2005-11-16 | Johnson & Johnson Medical Ltd | Enzyme-sensitive therapeutic wound dressings |
| WO2004042068A2 (en) | 2002-10-31 | 2004-05-21 | Northwestern University | Injectable and bioadhesive polymeric hydrogels as well as related methods of enzymatic preparation |
| US6863783B2 (en) | 2002-11-14 | 2005-03-08 | The Meow Mix Company | Method of producing electrostatically charged gelatin |
| CA2509622C (en) | 2002-12-16 | 2012-02-21 | Gunze Limited | Medical film comprising gelatin and reinforcing material |
| WO2005051979A1 (en) | 2003-02-21 | 2005-06-09 | Akzo Nobel N.V. | Prevention and/or delay of peptide/protein carbamylation in urea solutions utilizing non-ethylene diamine like compounds |
| JP2004283371A (ja) | 2003-03-20 | 2004-10-14 | Nagoya Industrial Science Research Inst | 医用材料 |
| US7019191B2 (en) | 2003-03-25 | 2006-03-28 | Ethicon, Inc. | Hemostatic wound dressings and methods of making same |
| US6923996B2 (en) | 2003-05-06 | 2005-08-02 | Scimed Life Systems, Inc. | Processes for producing polymer coatings for release of therapeutic agent |
| US8771649B2 (en) | 2003-05-30 | 2014-07-08 | Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno | Inducible release vehicles |
| WO2005006991A2 (en) | 2003-07-18 | 2005-01-27 | Chiroxia Limited | Device and method for fallopian tube occlusion |
| US7129210B2 (en) | 2003-07-23 | 2006-10-31 | Covalent Medical, Inc. | Tissue adhesive sealant |
| US7186684B2 (en) | 2003-08-07 | 2007-03-06 | Ethicon, Inc. | Hemostatic device containing a protein precipitate |
| DE10337789A1 (de) | 2003-08-14 | 2005-09-15 | 3M Espe Ag | Einzeldosisspritze für ein mehrkomponentiges Material |
| US7316822B2 (en) | 2003-11-26 | 2008-01-08 | Ethicon, Inc. | Conformable tissue repair implant capable of injection delivery |
| WO2005055958A2 (en) | 2003-12-09 | 2005-06-23 | Promethean Surgical Devices Llc | Improved surgical adhesive and uses therefor |
| US20080026444A1 (en) | 2003-12-24 | 2008-01-31 | Shionogi & Co., Ltd. | Process For Producing Protein-Polymer Complex |
| US7109163B2 (en) | 2004-01-30 | 2006-09-19 | Ethicon, Inc. | Hemostatic compositions and devices |
| US20050209441A1 (en) | 2004-03-22 | 2005-09-22 | Lile Jackson D | Process for promoting proper folding of human serum albumin using a human serum albumin ligand |
| JP4955534B2 (ja) | 2004-03-22 | 2012-06-20 | アクセスクロージャー，インク． | 血管穿孔をシールするための装置 |
| DE102004024635A1 (de) | 2004-05-12 | 2005-12-08 | Deutsche Gelatine-Fabriken Stoess Ag | Verfahren zur Herstellung von Formkörpern auf Basis von vernetzter Gelatine |
| WO2005120462A2 (en) | 2004-06-07 | 2005-12-22 | Callisyn Pharmaceuticals, Inc. | Biodegradable and biocompatible crosslinked polymer hydrogel prepared from pva and/or peg macromer mixtures |
| US20050281799A1 (en) | 2004-06-16 | 2005-12-22 | Glen Gong | Targeting damaged lung tissue using compositions |
| US7302083B2 (en) | 2004-07-01 | 2007-11-27 | Analogic Corporation | Method of and system for sharp object detection using computed tomography images |
| US7766891B2 (en) | 2004-07-08 | 2010-08-03 | Pneumrx, Inc. | Lung device with sealing features |
| EP1781182B1 (en) | 2004-07-08 | 2019-11-13 | PneumRx, Inc. | Pleural effusion treatment device |
| CA2573148C (en) | 2004-07-08 | 2013-11-26 | Pneumrx, Inc. | Lung device with sealing features |
| WO2006016809A1 (en) | 2004-08-12 | 2006-02-16 | Nederlandse Organisatie Voor Toegepast- Natuurwetenschappelijk Onderzoek Tno | A method for enzymatic cross-linking of a protein, cross-linked protein thus obtained and use thereof. |
| GB0420091D0 (en) | 2004-09-10 | 2004-10-13 | Univ Nottingham Trent | Medical implant materials |
| US20060100138A1 (en) | 2004-11-10 | 2006-05-11 | Olsen David R | Implantable collagen compositions |
| FR2878533B1 (fr) | 2004-11-26 | 2007-04-27 | Univ Cergy Pontoise | Biomateriau capable d'effectuer successivement une transition solution/gel puis une transition gel/solution |
| EP1848491A4 (en) | 2005-02-09 | 2009-08-19 | Childrens Medical Center | DEVICE FOR MIXING AND DELIVERING FLUIDS FOR TISSUE REPAIR |
| JP4685090B2 (ja) | 2005-02-14 | 2011-05-18 | 株式会社メドジェル | 医療用ハイドロゲル |
| US7485323B2 (en) | 2005-05-31 | 2009-02-03 | Gelita Ag | Process for making a low molecular weight gelatine hydrolysate and gelatine hydrolysate compositions |
| RU2007145085A (ru) | 2005-06-15 | 2009-07-20 | Ново Нордиск Хелс Кеа Аг (Ch) | Опосредованное трансглютаминазой коньюгирование гормона роста |
| CA2616865C (en) | 2005-07-28 | 2014-07-08 | Carnegie Mellon University | Biocompatible polymers and methods of use |
| DE102005041927B4 (de) | 2005-09-03 | 2013-02-28 | Bosch Rexroth Aktiengesellschaft | Aktives Netzfilter |
| DE102005054940A1 (de) | 2005-11-17 | 2007-05-24 | Gelita Ag | Verbundmaterial, insbesondere für die medizinische Anwendung , und Verfahren zu dessen Herstellung |
| EP1968617A4 (en) | 2005-12-06 | 2012-05-02 | Tyco Healthcare | BIOCOMPATIBLE TISSUE SEALING ADHESIVES AND AGENTS |
| CA2573472A1 (en) | 2006-01-23 | 2007-07-23 | Tyco Healthcare Group Lp | Biodegradable hemostatic compositions |
| JP4663548B2 (ja) | 2006-02-24 | 2011-04-06 | 株式会社小糸製作所 | 車両用前照灯の灯具ユニット |
| WO2007122232A2 (en) | 2006-04-24 | 2007-11-01 | Coloplast A/S | Gelatin non-woven structures produced by a non-toxic dry solvent spinning process |
| US20070246505A1 (en) | 2006-04-24 | 2007-10-25 | Medical Ventures Inc. | Surgical buttress assemblies and methods of uses thereof |
| KR20070104748A (ko) | 2006-04-24 | 2007-10-29 | 박현진 | 어류 젤라틴 하드 캅셀용 필름 형성 조성물 및 이의제조방법 |
| WO2007134118A2 (en) | 2006-05-09 | 2007-11-22 | Chulso Moon | Protein based composition and methods of using same |
| WO2008000655A2 (de) | 2006-06-27 | 2008-01-03 | Robert Bosch Gmbh | Verfahren und vorrichtung zur vermeidung von störungen eines funkübertragungssystems |
| DE102006033168A1 (de) | 2006-07-10 | 2008-01-17 | Gelita Ag | Verwendung von Gelatine und einem Vernetzungsmittel zur Herstellung einer vernetzenden therapeutischen Zusammensetzung |
| DE102006033167A1 (de) | 2006-07-10 | 2008-01-24 | Gelita Ag | Verwendung von Gelatine und einem Vernetzungsmittel zur Herstellung eines vernetzenden medizinischen Klebers |
| TWI436793B (zh) | 2006-08-02 | 2014-05-11 | Baxter Int | 快速作用之乾密封膠及其使用和製造方法 |
| CN101677822A (zh) | 2006-12-11 | 2010-03-24 | 普拉罗美德公司 | 灌注器官止血法 |
| EP2111239B1 (en) | 2006-12-15 | 2013-03-06 | Lifebond Ltd. | Gelatin-transglutaminase hemostatic dressings and sealants |
| US8133484B2 (en) * | 2006-12-15 | 2012-03-13 | Lifebond Ltd | Hemostatic materials and dressing |
| US8057426B2 (en) | 2007-01-03 | 2011-11-15 | Medtronic Vascular, Inc. | Devices and methods for injection of multiple-component therapies |
| US8088095B2 (en) | 2007-02-08 | 2012-01-03 | Medtronic Xomed, Inc. | Polymeric sealant for medical use |
| EP2125092A4 (en) | 2007-02-22 | 2012-03-14 | Pluromed Inc | USE OF REVERSIBLE HEAT-SENSITIVE POLYMERS FOR FLOW CONTROL OF A BIOLOGICAL LIQUID AFTER MEDICAL USE |
| US8189557B2 (en) | 2007-02-23 | 2012-05-29 | Texas Instruments Incorporated | Secondary synchronization channel design for OFDMA systems |
| AU2008280563B2 (en) | 2007-07-20 | 2013-10-10 | Imaflex, Inc. | Polymer composite film with barrier functionality |
| EP2187972B1 (en) | 2007-08-16 | 2013-07-17 | Carnegie Mellon University | Inflammation-regulating compositions and methods |
| US8221783B2 (en) | 2007-09-10 | 2012-07-17 | Boston Scientific Scimed, Inc. | Medical devices with triggerable bioadhesive material |
| WO2009073193A2 (en) | 2007-12-03 | 2009-06-11 | The Johns Hopkins University | Methods of synthesis and use of chemospheres |
| WO2009075329A1 (ja) * | 2007-12-11 | 2009-06-18 | Fujifilm Corporation | 分解性を調整したゼラチン組成物 |
| WO2009105614A2 (en) | 2008-02-22 | 2009-08-27 | Dermal Technologies, Llc | Compositions for tissue augmentation |
| CN102014973A (zh) | 2008-02-29 | 2011-04-13 | 弗罗桑医疗设备公司 | 用于促进止血和/或伤口愈合的装置 |
| KR101541702B1 (ko) | 2008-03-03 | 2015-08-04 | 옴릭스 바이오파머슈티컬스 리미티드 | 활성 성분을 포함하는 젤라틴 스펀지, 이의 제조 방법 및 용도 |
| US20100008989A1 (en) | 2008-06-12 | 2010-01-14 | Ishay Attar | Process for manufacture of gelatin solutions and products thereof |
| CA2728186A1 (en) | 2008-06-18 | 2009-12-23 | Lifebond Ltd | Methods and devices for use with sealants |
| EP2487206A3 (en) | 2008-06-18 | 2012-11-28 | Lifebond Ltd | Cross-linkable gelatin-based compositions |
| EP2543394A1 (en) | 2008-06-18 | 2013-01-09 | Lifebond Ltd | A method for enzymatic cross-linking of a protein |
| WO2010027471A2 (en) | 2008-09-04 | 2010-03-11 | The General Hospital Corporation | Hydrogels for vocal cord and soft tissue augmentation and repair |
| WO2010146582A2 (en) | 2009-06-15 | 2010-12-23 | Technion- Research And Development Foundation Ltd. | Reinforced surgical adhesives and sealants and their in-situ application |
| DK2442835T3 (da) | 2009-06-16 | 2015-03-16 | Baxter Int | Blodstillende svamp |
| US8771258B2 (en) | 2009-12-16 | 2014-07-08 | Baxter International Inc. | Hemostatic sponge |
| ES2551388T3 (es) | 2009-12-22 | 2015-11-18 | Lifebond Ltd | Modificación de agentes de entrecruzamiento enzimáticos para controlar las propiedades de las matrices entrecruzadas |
| US9297464B1 (en) | 2014-09-11 | 2016-03-29 | Beto Engineering & Marketing Co., Ltd. | Air pump having pivotal attachment |
-
2010
- 2010-12-22 ES ES10814706.7T patent/ES2551388T3/es active Active
- 2010-12-22 BR BR112012015029A patent/BR112012015029A2/pt not_active Application Discontinuation
- 2010-12-22 EP EP10814706.7A patent/EP2515957B1/en active Active
- 2010-12-22 JP JP2012545517A patent/JP5796860B2/ja active Active
- 2010-12-22 CA CA2782863A patent/CA2782863A1/en not_active Abandoned
- 2010-12-22 WO PCT/IB2010/056008 patent/WO2011077388A1/en active Application Filing
- 2010-12-22 US US13/517,906 patent/US9066991B2/en active Active
- 2010-12-22 AU AU2010334412A patent/AU2010334412B2/en not_active Ceased
- 2010-12-22 CN CN201080057151.0A patent/CN102711853B/zh active Active
- 2010-12-22 DK DK10814706.7T patent/DK2515957T3/da active
- 2010-12-22 EP EP15160796.7A patent/EP2963111A1/en not_active Withdrawn
-
2012
- 2012-06-12 IL IL220325A patent/IL220325A/en active IP Right Grant
-
2015
- 2015-04-25 US US14/696,390 patent/US10202585B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP5796860B2 (ja) | 2015-10-21 |
| ES2551388T3 (es) | 2015-11-18 |
| EP2515957B1 (en) | 2015-07-29 |
| JP2013515128A (ja) | 2013-05-02 |
| AU2010334412A1 (en) | 2012-06-07 |
| WO2011077388A1 (en) | 2011-06-30 |
| CA2782863A1 (en) | 2011-06-30 |
| US10202585B2 (en) | 2019-02-12 |
| CN102711853A (zh) | 2012-10-03 |
| BR112012015029A2 (pt) | 2017-06-27 |
| IL220325A (en) | 2016-02-29 |
| US9066991B2 (en) | 2015-06-30 |
| EP2963111A1 (en) | 2016-01-06 |
| US20120270810A1 (en) | 2012-10-25 |
| AU2010334412B2 (en) | 2016-02-04 |
| EP2515957A1 (en) | 2012-10-31 |
| CN102711853B (zh) | 2015-05-20 |
| US20150291939A1 (en) | 2015-10-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2515957T3 (da) | Ændring af enzymatiske tværbindere for styring af egenskaber ved tværbundne matrixer | |
| Pandey et al. | Mussel-inspired bioadhesives in healthcare: design parameters, current trends, and future perspectives | |
| JP6258868B2 (ja) | 止血創傷被覆材 | |
| US5527893A (en) | Water insoluble derivatives of polyanionic polysaccharides | |
| Gonen-Wadmany et al. | Protein–polymer conjugates for forming photopolymerizable biomimetic hydrogels for tissue engineering | |
| US9044456B2 (en) | Cross-linked compositions | |
| ES2383550T3 (es) | Material sellante seco de acción rápida y métodos para su uso y elaboración | |
| US20140187487A1 (en) | Affinity-based controlled release system | |
| KR101664444B1 (ko) | 생분해성 의료용 접착제 또는 실란트 조성물 | |
| US20160243275A1 (en) | Polymer hydrogel adhesives formed with multiple crosslinking mechanisms at physiologic ph | |
| US20050276858A1 (en) | Bifunctional-modified hydrogels | |
| US20140193386A1 (en) | Method for enzymatic cross-linking of a protein | |
| JP2019216755A (ja) | 止血材 | |
| US20060078962A1 (en) | Polysaccharide-based polymers and methods of making the same | |
| JP6367979B2 (ja) | 外科用シーラント | |
| JP4669919B2 (ja) | 医療用組成物 | |
| US20230148082A1 (en) | Jellyfish collagen use | |
| JP4397015B2 (ja) | ゲル化組成物 |